Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12500029rdf:typepubmed:Citationlld:pubmed
pubmed-article:12500029lifeskim:mentionsumls-concept:C2709248lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C0042396lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C0032824lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C0242184lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C1414262lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C1414263lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C2348358lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C0205430lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C1720127lld:lifeskim
pubmed-article:12500029lifeskim:mentionsumls-concept:C1514555lld:lifeskim
pubmed-article:12500029pubmed:issue1lld:pubmed
pubmed-article:12500029pubmed:dateCreated2002-12-24lld:pubmed
pubmed-article:12500029pubmed:abstractTextThe aims of this study were to investigate the effects of a selective ETA (BQ-123), a selective ETB (BQ-788), and a specific mixed ETA/ETB receptor antagonist (bosentan) on the pulmonary vasoconstriction induced by hypoxia in the isolated perfused rat lung, and the role of nitric oxide, adenosine triphosphate-sensitive (KATP), large conductance Ca+-activated (BKCa) and 4-aminopyridine-sensitive voltage-gated K channels (K+) in the relaxant effects of the selective ETA receptor antagonist BQ-123 and a protein kinase C inhibitor, bisindolylmaleimide I. K+ channels were inhibited by glibenclamide, charybdotoxin, and 4-aminopyridine and nitric oxide synthase by L-NG-nitroarginine methyl ester (L-NAME). Hypoxic ventilation produced a significant pressure response (+57%, p < 0.001). BQ-123, bosentan, and bisindolylmaleimide I induced a concentration-dependent decrease of the hypoxic pressure response (p < 0.001), whereas BQ-788 did not exhibit any inhibitory effect against hypoxic pressure response. Glibenclamide, charybdotoxin, and 4-aminopyridine partially opposed the inhibitory effects elicited by BQ-123 (p < 0.05), but L-NAME did not modify these effects. The effects of bisindolylmaleimide I on hypoxic pressure response were unaffected by glibenclamide, charybdotoxin, or 4-aminopyridine. The authors conclude that (a) ETA receptors and protein kinase C are involved in the modulation of hypoxic pulmonary vasoconstriction; and (b) the ETA antagonist BQ-123 opposes hypoxic pulmonary vasoconstriction through KATP, KV, and BKCa channels, differing in this from the protein kinase C inhibitor bisindolylmaleimide I. These results suggest that BQ-123 operates through a mechanism independent of bisindolylmaleimide I-inhibited protein kinase C isoforms.lld:pubmed
pubmed-article:12500029pubmed:languageenglld:pubmed
pubmed-article:12500029pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:citationSubsetIMlld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12500029pubmed:statusMEDLINElld:pubmed
pubmed-article:12500029pubmed:monthJanlld:pubmed
pubmed-article:12500029pubmed:issn0160-2446lld:pubmed
pubmed-article:12500029pubmed:authorpubmed-author:RochetteLucLlld:pubmed
pubmed-article:12500029pubmed:authorpubmed-author:BardouMarcMlld:pubmed
pubmed-article:12500029pubmed:authorpubmed-author:GoirandFranço...lld:pubmed
pubmed-article:12500029pubmed:authorpubmed-author:GuerardPascal...lld:pubmed
pubmed-article:12500029pubmed:authorpubmed-author:DumasJean-Pau...lld:pubmed
pubmed-article:12500029pubmed:authorpubmed-author:DumasMoniqueMlld:pubmed
pubmed-article:12500029pubmed:issnTypePrintlld:pubmed
pubmed-article:12500029pubmed:volume41lld:pubmed
pubmed-article:12500029pubmed:ownerNLMlld:pubmed
pubmed-article:12500029pubmed:authorsCompleteYlld:pubmed
pubmed-article:12500029pubmed:pagination117-25lld:pubmed
pubmed-article:12500029pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:meshHeadingpubmed-meshheading:12500029...lld:pubmed
pubmed-article:12500029pubmed:year2003lld:pubmed
pubmed-article:12500029pubmed:articleTitleETA, mixed ETA/ETB receptor antagonists, and protein kinase C inhibitor prevent acute hypoxic pulmonary vasoconstriction: influence of potassium channels.lld:pubmed
pubmed-article:12500029pubmed:affiliationLaboratoire de Physiopathologie et Pharmacologie Cardiovasculaires Expérimentales, Faculté de Médecine, Dijon, France. Francoise.Goirand@u-bourgogne.frlld:pubmed
pubmed-article:12500029pubmed:publicationTypeJournal Articlelld:pubmed